Celgene Expands Relationship with Medidata in Enterprise Clinical Trial Technology

NEW YORK--()--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Celgene Corporation has expanded its eight-year technology relationship with Medidata to add the Medidata Clinical Cloud® as its enterprise technology platform for all clinical trials worldwide.

To drive therapeutic excellence in the interest of patients through a sustainable pipeline of cancer and inflammatory disease treatments, Celgene is utilizing Medidata's unified technology platform to enhance capabilities in data management, study planning and design, trial operations, analytics and patient engagement.

"Celgene's deep commitment to patients, disruptive science and disease-altering medical innovation is at the heart of their clinical development strategy and, more broadly, the success that they are having in driving medical advances in many of the world's difficult-to-treat diseases," said Tarek Sherif, Medidata's chief executive officer. "We are in the early days of a renaissance in drug discovery, and Medidata's Clinical Cloud is playing a critical role in helping to power the kind of innovation that will improve the lives of patients around the world."

Primarily a Medidata Rave® (electronic data capture, management and reporting) customer since 2008, Celgene will expand its use of the Medidata Clinical Cloud to include Medidata Designer® (study and protocol design); Medidata Grants Manager® (site budgeting and planning); Safety Gateway (safety reporting); Medidata CTMS® (clinical trial management); Medidata SQM (site quality management) and Medidata Patient Cloud ePRO (electronic patient-reported outcomes). Celgene is also leveraging one of Medidata's turnkey clinical analytics offerings, Medidata Insights™, which provides advanced metrics, visualizations and the most powerful set of industry data and benchmarks.

"Drug development is becoming more complex by the day, with researchers exploring vast genomes and proteomes increasing prospects to control or cure disease through precision medicine. Medidata is providing Celgene and a rapidly growing list of other global life sciences companies with an integrated platform and the fundamental analytics and tools needed to optimize drug development programs," said Glen de Vries, Medidata's president. "We are thrilled to deepen our relationship with Celgene, a company that shares our passion for pushing the frontiers of science and technology and improving global health."


Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.